Abstract
The recent report from the American Academy of Pediatrics on the prevention of iron deficiency and iron deficiency anemia recommended increased iron intake for breast fed infants beginning at 4 months of age. This recommendation has not been without controversy. This paper will review the reasoning behind these new recommendations and include a physiologic review of iron metabolism as well as its physiologic importance including its role in neurodevelopment. It will review the diagnosis of both iron deficiency and iron deficiency anemia and how to prevent them in the breastfed infant. This includes introducing medicinal iron at 4 months of age and introducing foods that are rich in heme iron (red meat) when complementary feedings are introduced.
Keywords: Infants, breastfeeding, iron deficiency, iron deficiency anemia, neuroedevelopment
Current Pediatric Reviews
Title:The Iron Requirement of Breastfeeding Infants
Volume: 8 Issue: 4
Author(s): Frank R. Greer
Affiliation:
Keywords: Infants, breastfeeding, iron deficiency, iron deficiency anemia, neuroedevelopment
Abstract: The recent report from the American Academy of Pediatrics on the prevention of iron deficiency and iron deficiency anemia recommended increased iron intake for breast fed infants beginning at 4 months of age. This recommendation has not been without controversy. This paper will review the reasoning behind these new recommendations and include a physiologic review of iron metabolism as well as its physiologic importance including its role in neurodevelopment. It will review the diagnosis of both iron deficiency and iron deficiency anemia and how to prevent them in the breastfed infant. This includes introducing medicinal iron at 4 months of age and introducing foods that are rich in heme iron (red meat) when complementary feedings are introduced.
Export Options
About this article
Cite this article as:
R. Greer Frank, The Iron Requirement of Breastfeeding Infants, Current Pediatric Reviews 2012; 8 (4) . https://dx.doi.org/10.2174/157339612803307741
DOI https://dx.doi.org/10.2174/157339612803307741 |
Print ISSN 1573-3963 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6336 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Identification and Characterization of the Binding Sites of P-Glycoprotein for Multidrug Resistance-Related Drugs and Modulators
Current Medicinal Chemistry - Anti-Cancer Agents Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism Tyrosine Kinase Mutations in Human Cancer
Current Molecular Medicine Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets Mast Cells and Basophils: Trojan Horses of Conventional Lin- Stem/Progenitor Cell Isolates
Current Pharmaceutical Design DNA Methyltransferases Inhibitors from Natural Sources
Current Topics in Medicinal Chemistry Cancer Cell Reprogramming: Stem Cell Differentiation Stage Factors and An Agent Based Model to Optimize Cancer Treatment
Current Pharmaceutical Biotechnology Tumor Dormancy and the Angiogenic Switch: Possible Implications of Bone Marrow- Derived Cells
Current Pharmaceutical Design Stem Cells and Cardiovascular Repair: A Role for Natural and Synthetic Molecules Harboring Differentiating and Paracrine Logics
Cardiovascular & Hematological Agents in Medicinal Chemistry Signal transduction in Acute Myeloid Leukemia – Implications for Novel Therapeutic Concepts.
Current Cancer Drug Targets Recent Patents on Proteasome Inhibitors of Natural Origin
Recent Patents on Anti-Cancer Drug Discovery Immunosuppressive Therapies in Solid Organ Transplantation
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) NF-κB Inhibitors in Head and Neck Cancer
Letters in Drug Design & Discovery Stem Cell Transplantation for Hematological Malignancies: Prospects for Personalized Medicine and Co-therapy with Mesenchymal Stem Cells
Current Pharmacogenomics and Personalized Medicine The Role of CD40 Expression in Dendritic Cells in Cancer Biology; A Systematic Review
Current Cancer Drug Targets Proteomics of p53 in Diagnostics and Therapy of Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Anti-TNFs for Postoperative Recurrence in Crohns Disease: The Ifs and Hows
Current Drug Targets Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets